Stephen L. Atkin, MBBS, PhD
Professor of Medicine

Phone: (+974) 4492 8263
Stephen L. Atkin

PROFILE

Dr. Stephen L. Atkin joined Weill Cornell Medicine - Q (WCM-Q) in January 2014 as Professor of Medicine. He has an established international reputation in diabetes and obesity research, encompassing both polycystic ovary syndrome and the metabolic syndrome, has led pharmaceutical and nutritional clinical trials teams for these studies in the U.K, and is regularly invited to speak at international forums and to participate in research panels for these conditions.

Prior to coming to WCM-Q, Dr. Atkin was Professor of Diabetes, Endocrinology, and Metabolism and Head of Academic Diabetes and Endocrinology at Hull York Medical School, University of Hull and Honorary Consultant in the Department of Diabetes and Endocrinology at Hull and East Yorkshire Hospitals. He has extensive experience teaching medical and graduate students and was the regional coordinator for the diabetes and endocrinology graduate training program for the Royal College of Physicians/Diabetes U.K. Endocrine Society covering a large part of central England. Under his leadership, the department became an internationally respected center for diabetes, endocrinology, obesity, and nutritional research.

During his career, Dr. Atkin has received a number of important research awards, including recent funding from the Biotechnology and Biological Sciences Research Council, the Food Standards Agency, and the Higher Education Funding Council that amount to over nine million US Dollars. Additionally, he has led the Humber Obesity, Nutrition, Education, and Innovation (HONEI) project (www.honei.co.uk) that focuses on clinical and translational research on functional food in health and disease. He has published over one hundred and forty articles in peer-reviewed journals, including work in Diabetes Care, PLOS ONE, and the Journal of Clinical Endocrinology and Metabolism, and several book chapters and reviews. He is a grant referee for several major funding bodies, such as the Wellcome Foundation and the British Heart Foundation; a journal reviewer for several journals, including the Journal of the American Medical Association, Diabetes Care, and the Journal of Clinical Endocrinology and Metabolism; he is the series advisor on “rational testing” for the British Medical Journal and an Academic Editor for PLOS ONE and the International Journal of Endocrinology.

SELECTED PUBLICATIONS
  • Kilpatrick ES, Rigby AS, Atkin SL, Barth JH. Glycemic control in the 12 months following a change to SI hemoglobin A1c reporting units. Clinical chemistry. 2013 Jun 21: doi: 10.1373/clinchem.2013.206334. [Epub ahead of print].
  • Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, Bain S, Johansen T, Begtrup K, Birkeland KI. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes care. 2013 Apr;36(4):858-64.
  • Sathyapalan T, Shepherd J, Atkin SL, Kilpatrick ES. The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study. Diabetes, obesity & metabolism. 2013 Aug;15(8):767-9.
  • Sathyapalan T, Shepherd J, Kilpatrick ES, Coady AM, Atkin SL. Atorvastatin therapy Reduces Malondialdehyde in patients with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism 2012;97(11):3951-5
  • Sathyapalan T, Manuchehri AM, Thatcher NJ, Rigby AS, Chapman T, Kilpatrick ES, Atkin SL. The effect of soy phytoestrogen supplementation on thyroid status and cardiovascular risk markers in patients with subclinical hypothyroidism: a randomized, double-blind, crossover study. The Journal of clinical endocrinology and metabolism. 2011 May;96(5):1442-9.
  • Sathyapalan T, Shepherd J, Arnett C, Coady AM, Kilpatrick ES, Atkin SL. Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical chemistry. 2010 Nov;56(11):1696-700.
  • Ng JM, Cooke M, Bhandari S, Atkin SL, Kilpatrick ES. The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease. Diabetes care. 2010 Nov;33(11):2310-3
  • Kilpatrick ES, Rigby AS, Atkin SL. The role of blood pressure variability in the development of nephropathy in type 1 diabetes. Diabetes care. 2010 Nov;33(11):2442-7.



Last modified on Tuesday, 19-Jul-2016 15:08:31 +03